乐天堂fun88

Officials from the Ministry of Public Health of Thailand met with the Chairman of Shenzhen Cell Valley to discuss the industrial layout of cell therapy.

Date:10-02  Hits:  Belong to:News & Events

On September 30, 2024, at the invitation of the Thai government, Dr. Shi Yuanyuan, Chairman of Shenzhen Cell Valley, led a delegation to Thailand and held high-level talks with officials from the Ministry of Public Health, Department of Health Service Support, at the Thai Government House. The meeting aimed to advance Shenzhen Cell Valley’s cell therapy industrial projects in Thailand and explore in-depth cooperation with local government authorities, medical institutions and universities in the field of cell therapy.

Present at the meeting were:Dr. Samart Thirasak, Deputy Permanent Secretary of the Department of Health Service Support, Ministry of Public Health of Thailand;Dr. Kanyarat Kuisuwan, Deputy Director of the Medical Industry Promotion Department;Ms. Chayavee Khamwattanachi, Leader of the Assisted Reproductive Technology Unit, Department of Healing and Treatment;Dr. Shi Yuanyuan, Chairman of Shenzhen Cell Valley;

Dr. Fu Yuchen, Assistant to the Chairman;and Dr. Sranyoo Chanate, Chief Executive Officer of Kluaynamthai Hospital Group, together with other partners.

During the talks, Dr. Shi Yuanyuan elaborated on the leading advantages and market prospects of Shenzhen Cell Valley in cell therapy technologies, and expressed a strong desire to establish long-term strategic cooperation with medical and academic institutions in Thailand.Dr. Samart spoke highly of Shenzhen Cell Valley’s investment and technical cooperation plans, and pledged that the Thai government would provide comprehensive support and necessary policy conveniences for the smooth implementation of the project.

In addition, the two sides conducted in-depth discussions on Shenzhen Cell Valley assisting Thailand in establishing a full-process regulatory system for cell therapy that meets international standards, particularly the introduction of accreditations from FACT (Foundation for the Accreditation of Cellular Therapy) and AABB (American Association of Blood Banks). This exchange laid a solid foundation for the policy standardization of Thailand’s cell therapy industry.

The two sides also held constructive discussions on biomedical research and development, clinical research cooperation, and talent cultivation.

This meeting has further deepened the mutual trust between Shenzhen Cell Valley and Thailand’s Ministry of Public Health, laying a solid foundation for future market expansion in Thailand.Our company sincerely appreciates the support from the Thai government and looks forward to reaching concrete cooperation agreements as soon as possible, so as to jointly promote the vigorous development of the cell therapy industry in Thailand.


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact:Ms. Lai

Email:laijiaqi@wfzydp.com

Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Shenzhen Cell Valley Biopharmaceutical Co., Ltd. is a leading one-stop comprehensive outsourcing service provider for China’s cell and gene therapy industry. It is also among the first domestic CRO/CDMO enterprises to hold GMP-compliant industrial production capabilities for clinical-grade retroviral vectors. As a key project for the construction of Shenzhen’s public technical service platform for CRO/CDMO, the company has been listed in the city’s newly announced "20+8" strategic emerging industries initiative.
Shenzhen Cell Valley is equipped with the capacity to conduct standardized and industrialized production of GMP-grade cellular products including CAR-T cells. Its core production lines cover a full spectrum of cellular products such as CAR-T, CAR-NK, CAR-M, γδT, TIL and TCR-T. In addition, the company runs production lines for a diverse range of viral vectors (including RVV, LVV and AAV) and non-viral vectors, as well as for cellular raw materials for therapeutic development—such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses and vaccines.
 Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书:(粤)-非经营性-2022-0426  Technical Support:YouDian Software